Related Experiment Video
Updated: Feb 2, 2026

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1
Published on: February 25, 2016
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK
Daniel J Wood1, Svitlana Korolchuk1, Natalie J Tatum1
1Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Abstract:
Dysregulation of the cell cycle characterizes many cancer subtypes, providing a rationale for developing cyclin-dependent kinase (CDK) inhibitors. Potent CDK2 inhibitors might target certain cancers in which CCNE1 is amplified. However, current CDK2 inhibitors also inhibit CDK1, generating a toxicity liability. We have used biophysical measurements and X-ray crystallography to investigate the ATP-competitive inhibitor binding properties of cyclin-free and cyclin-bound CDK1 and CDK2. We show that these kinases can readily be distinguished by such inhibitors when cyclin-free, but not when cyclin-bound. The basis for this discrimination is unclear from either inspection or molecular dynamics simulation of ligand-bound CDKs, but is reflected in the contacts made between the kinase N- and C-lobes. We conclude that there is a subtle but profound difference between the conformational energy landscapes of cyclin-free CDK1 and CDK2. The unusual properties of CDK1 might be exploited to differentiate CDK1 from other CDKs in future cancer therapeutic design.
Insights
Researchers explored cyclin-dependent kinase (CDK) inhibitors for cancer therapy. They found differences in cyclin-free CDK1 and CDK2 binding properties, suggesting new therapeutic strategies for targeting specific cancers.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Cell cycle dysregulation is a hallmark of many cancers, driving interest in cyclin-dependent kinase (CDK) inhibitors.
- CDK2 inhibitors show promise for cancers with CCNE1 amplification, but off-target inhibition of CDK1 causes toxicity.
Purpose of the Study:
- To investigate the binding properties of ATP-competitive inhibitors with cyclin-free and cyclin-bound CDK1 and CDK2.
- To understand the basis for differential inhibitor binding between CDK1 and CDK2.
Main Methods:
- Biophysical measurements
- X-ray crystallography
- Molecular dynamics simulations
Main Results:
- Inhibitors can distinguish between cyclin-free CDK1 and CDK2, but not when they are cyclin-bound.
- Differences in inhibitor binding correlate with contacts between the N- and C-lobes of the kinases.
- A subtle but significant difference exists in the conformational energy landscapes of cyclin-free CDK1 and CDK2.
Conclusions:
- The distinct conformational properties of cyclin-free CDK1 and CDK2 offer opportunities for developing selective kinase inhibitors.
- Exploiting CDK1's unique characteristics could lead to improved cancer therapeutics with reduced toxicity.
Related Concept Videos
Inhibition of Cdk Activity
Conformity
Conservation of Mechanical Energy
When a...
Mechanical Protein Functions
What is Energy?
Gibbs Free Energy

